The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation., Genes & Development, vol.9, issue.5, pp.534-546, 1995. ,
Identifying tumor suppressors in genetic mosaics: The Drosophila lats gene encodes a putative protein kinase, Development, vol.121, pp.1053-1063, 1995. ,
The Hippo Signaling Pathway in Development and Cancer, Developmental Cell, vol.19, issue.4, pp.491-505, 2010. ,
The Hippo Pathway, Cold Spring Harbor Perspectives in Biology, vol.4, issue.8, pp.a011288-a011288, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-02989075
The Hippo pathway and apico?basal cell polarity, Biochemical Journal, vol.436, issue.2, pp.213-224, 2011. ,
salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines, Cell, vol.110, issue.4, pp.467-478, 2002. ,
Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila, Development, vol.129, issue.24, pp.5719-5730, 2002. ,
The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP, Cell, vol.122, issue.3, pp.421-434, 2005. ,
The TEAD/TEF Family Protein Scalloped Mediates Transcriptional Output of the Hippo Growth-Regulatory Pathway, Developmental Cell, vol.14, issue.3, pp.388-398, 2008. ,
The TEAD/TEF Family of Transcription Factor Scalloped Mediates Hippo Signaling in Organ Size Control, Developmental Cell, vol.14, issue.3, pp.377-387, 2008. ,
Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product, Oncogene, vol.9, pp.2145-2152, 1994. ,
Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals, Cell, vol.130, issue.6, pp.1120-1133, 2007. ,
The Hippo Signaling Pathway Components Lats and Yap Pattern Tead4 Activity to Distinguish Mouse Trophectoderm from Inner Cell Mass, Developmental Cell, vol.16, issue.3, pp.398-410, 2009. ,
Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity, The EMBO Journal, vol.23, issue.18, pp.3677-3688, 2004. ,
Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction, Nature Genetics, vol.21, issue.2, pp.182-186, 1999. ,
TEAD mediates YAP-dependent gene induction and growth control, Genes & Development, vol.22, issue.14, pp.1962-1971, 2008. ,
Tao-1 Phosphorylates Hippo/MST Kinases to Regulate the Hippo-Salvador-Warts Tumor Suppressor Pathway, Developmental Cell, vol.21, issue.5, pp.888-895, 2011. ,
The Sterile 20-like Kinase Tao-1 Controls Tissue Growth by Regulating the Salvador-Warts-Hippo Pathway, Developmental Cell, vol.21, issue.5, pp.896-906, 2011. ,
The Drosophila Mst Ortholog, hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis, Cell, vol.114, issue.4, pp.457-467, 2003. ,
The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis, Genes & Development, vol.17, issue.20, pp.2514-2519, 2003. ,
The Biology of YAP/TAZ: Hippo Signaling and Beyond, Physiological Reviews, vol.94, issue.4, pp.1287-1312, 2014. ,
Regulation of the Hippo pathway in cancer biology, Cellular and Molecular Life Sciences, vol.75, issue.13, pp.2303-2319, 2018. ,
Crumbs Regulates Salvador/Warts/Hippo Signaling in Drosophila via the FERM-Domain Protein Expanded, Current Biology, vol.20, issue.7, pp.582-590, 2010. ,
The neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation, vol.127, pp.1315-1324, 2000. ,
Oncogenic Signaling Pathways in The Cancer Genome Atlas, Cell, vol.173, issue.2, pp.321-337.e10, 2018. ,
Role of the Hippo Pathway in Fibrosis and Cancer, Cells, vol.8, issue.5, p.468, 2019. ,
YAP/TAZ at the Roots of Cancer, Cancer Cell, vol.29, issue.6, pp.783-803, 2016. ,
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis, Cancer Cell, vol.31, issue.1, pp.35-49, 2017. ,
LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma, Cancer Research, vol.71, issue.3, pp.873-883, 2011. ,
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation, Pathology International, vol.61, issue.6, pp.331-344, 2011. ,
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma, Science Translational Medicine, vol.3, issue.98, pp.98ra82-98ra82, 2011. ,
Regulation of TEAD Transcription Factors in Cancer Biology, Cells, vol.8, issue.6, p.600, 2019. ,
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer, Cell, vol.163, issue.4, pp.811-828, 2015. ,
The Control of Vascular Integrity by Endothelial Cell Junctions: Molecular Basis and Pathological Implications, Developmental Cell, vol.16, issue.2, pp.209-221, 2009. ,
Tumor angiogenesis and vascular normalization: alternative therapeutic targets, Angiogenesis, vol.20, issue.4, pp.409-426, 2017. ,
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways, Proceedings of the National Academy of Sciences, vol.94, issue.3, pp.861-866, 1997. ,
Differential gene expression by endothelial cells in distinct angiogenic states, European Journal of Biochemistry, vol.267, issue.9, pp.2820-2830, 2000. ,
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein, Genes & Development, vol.25, issue.1, pp.51-63, 2011. ,
The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry, Cells, vol.8, issue.5, p.407, 2019. ,
Vascular remodeling by intussusceptive angiogenesis, Cell and Tissue Research, vol.314, issue.1, pp.107-117, 2003. ,
Angiomotin regulates endothelial cell migration during embryonic angiogenesis, Genes & Development, vol.21, issue.16, pp.2055-2068, 2007. ,
YAP1 Recruits c-Abl to Protect Angiomotin-Like 1 from Nedd4-Mediated Degradation, PLoS ONE, vol.7, issue.4, p.e35735, 2012. ,
CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity, Journal of Biological Chemistry, vol.282, issue.42, pp.30643-30657, 2007. ,
Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival, Current Protein & Peptide Science, vol.11, issue.6, pp.471-484, 2010. ,
Regulation of Hippo signaling by actin remodeling, BMB Reports, vol.51, issue.3, pp.151-156, 2018. ,
Regulation of YAP/TAZ Activity by Mechanical Cues: An Experimental Overview, Methods in Molecular Biology, vol.1893, pp.183-202, 2018. ,
Role of YAP/TAZ in mechanotransduction, Nature, vol.474, issue.7350, pp.179-183, 2011. ,
Flow-Dependent Endothelial YAP Regulation Contributes to Vessel Maintenance, Developmental Cell, vol.40, issue.6, pp.523-536.e6, 2017. ,
Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice, vol.121, pp.1845-1854, 1995. ,
TGF-? Receptor Type II Deficiency Results in Defects of Yolk Sac Hematopoiesis and Vasculogenesis, Developmental Biology, vol.179, issue.1, pp.297-302, 1996. ,
Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice, The EMBO Journal, vol.20, issue.7, pp.1663-1673, 2001. ,
TGF-? Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation, Molecular Cell, vol.63, issue.1, pp.156-166, 2016. ,
Zyxin-Siah2?Lats2 axis mediates cooperation between Hippo and TGF-? signalling pathways, Nature Communications, vol.7, issue.1, 2016. ,
Probing the Fifty Shades of EMT in Metastasis, Trends in Cancer, vol.2, issue.2, pp.65-67, 2016. ,
EMT, the cytoskeleton, and cancer cell invasion, Cancer and Metastasis Reviews, vol.28, issue.1-2, pp.15-33, 2009. ,
The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer, Molecular Oncology, vol.9, issue.6, pp.1091-1105, 2015. ,
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon, Proceedings of the National Academy of Sciences, vol.103, issue.33, pp.12405-12410, 2006. ,
TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway, Molecular and Cellular Biology, vol.28, issue.7, pp.2426-2436, 2008. ,
Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation, Nature Cell Biology, vol.18, issue.9, pp.917-929, 2016. ,
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival, Cell, vol.158, issue.1, pp.171-184, 2014. ,
Switch-like enhancement of epithelial-mesenchymal transition by YAP through feedback regulation of WT1 and Rho-family GTPases, Nature Communications, vol.10, issue.1, pp.1-15, 2019. ,
Yes?associated protein (YAP) predicts poor prognosis and regulates progression of esophageal squamous cell cancer through epithelial?mesenchymal transition, Experimental and Therapeutic Medicine, vol.18, pp.2993-3001, 2019. ,
YAP Promotes Migration and Invasion of Human Glioma Cells, Journal of Molecular Neuroscience, vol.64, issue.2, pp.262-272, 2018. ,
Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization, Biochemical and Biophysical Research Communications, vol.520, issue.2, pp.263-268, 2019. ,
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer, Experimental Cell Research, vol.350, issue.1, pp.218-225, 2017. ,
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling, Cell, vol.150, issue.4, pp.780-791, 2012. ,
YAP modulates TGF-?1-induced simultaneous apoptosis and EMT through upregulation of the EGF receptor, Scientific Reports, vol.7, issue.1, 2017. ,
Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction, Molecular Cell, vol.72, issue.2, pp.328-340.e8, 2018. ,
PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway, Oncotarget, vol.6, issue.33, pp.34788-34799, 2015. ,
Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition, Journal of Cell Science, vol.127, issue.7, pp.1523-1536, 2014. ,
Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion., Molecular and Cellular Biology, vol.16, issue.4, pp.1326-1334, 1996. ,
Connective tissue growth factor (CTGF) and cancer progression, Journal of Biomedical Science, vol.15, issue.6, pp.675-685, 2008. ,
Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry, Cancer Cell, vol.25, issue.6, pp.831-845, 2014. ,
Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice, Cancer Research, vol.75, issue.16, pp.3384-3397, 2015. ,
Knockdown of the Hippo transducer YAP reduces proliferation and promotes apoptosis in the Jurkat leukemia cell, Molecular Medicine Reports, vol.18, pp.5379-5388, 2018. ,
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis, Genes & Development, vol.26, issue.1, pp.54-68, 2012. ,
Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling, Oncogene, vol.34, issue.48, pp.5879-5889, 2015. ,
Metastasis: recent discoveries and novel treatment strategies, The Lancet, vol.369, issue.9574, pp.1742-1757, 2007. ,
Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours, Virchows Archiv, vol.425, issue.2, pp.107-112, 1994. ,
Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance, Journal of Cancer, vol.6, issue.10, pp.1005-1010, 2015. ,
Hippo pathway effectors YAP1/TAZ induce an EWS?FLI1 ?opposing gene signature and associate with disease progression in Ewing sarcoma, The Journal of Pathology, vol.250, issue.4, pp.374-386, 2020. ,
EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin ?5?1-mediated YAP activation in Ewing sarcoma, British Journal of Cancer, vol.121, issue.11, pp.922-933, 2019. ,
EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma, Oncogene, vol.36, issue.43, pp.5995-6005, 2017. ,
BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma, Oncogene, vol.30, issue.17, pp.2077-2085, 2010. ,
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, pp.iii113-iii123, 2014. ,
Malignant tumors of the osteogenic matrix, European Journal of Radiology, vol.27, pp.S98-S109, 1998. ,
WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition, Pathology, vol.46, issue.2, pp.95-104, 2014. ,
Bone sarcomas: ESMO?PaedCan?EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.29, pp.iv79-iv95, 2018. ,
Osteosarcoma, Cancer Treatment and Research, vol.162, pp.65-92, 2014. ,
Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and ?1-integrin in conventional osteosarcoma, Oncotarget, vol.7, issue.40, pp.64702-64710, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01482390
The Role and Clinical Significance of Yes-Associated Protein 1 in Human Osteosarcoma, International Journal of Immunopathology and Pharmacology, vol.26, issue.1, pp.157-167, 2013. ,
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells, Nature Communications, vol.6, issue.1, p.6411, 2015. ,
Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma, Oncogene, vol.37, issue.33, pp.4626-4632, 2018. ,
PPAR? agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity, Oncotarget, vol.7, issue.38, pp.60954-60970, 2016. ,
TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma, Biochemical and Biophysical Research Communications, vol.488, issue.2, pp.297-302, 2017. ,
Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGF? signaling and defects in the Hippo signaling cascade, Cell Cycle, vol.11, issue.18, pp.3373-3379, 2012. ,
Crosstalk between Hippo and TGF?: Subcellular Localization of YAP/TAZ/Smad Complexes, Journal of Molecular Biology, vol.427, issue.21, pp.3407-3415, 2015. ,
Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases, Oncotarget, vol.6, issue.16, pp.14413-14427, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01793498
Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma, Clinical Cancer Research, vol.20, issue.19, pp.5097-5112, 2014. ,
Transforming Growth Factor-? Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment, Frontiers in Oncology, vol.8, p.133, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01814333
CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells, Molecular Cancer, vol.17, issue.1, 2018. ,
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells, Journal of Experimental & Clinical Cancer Research, vol.38, issue.1, 2019. ,
Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1, Experimental Cell Research, vol.387, issue.2, p.111804, 2020. ,
Repurposing of Drugs Targeting YAP-TEAD Functions, Cancers, vol.10, issue.9, p.329, 2018. ,
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP, Genes & Development, vol.26, issue.12, pp.1300-1305, 2012. ,
C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC, Oncotarget, vol.9, issue.1, pp.668-679, 2017. ,
?Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines?, Chemico-Biological Interactions, vol.312, p.108813, 2019. ,
The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation, Experimental Eye Research, vol.124, pp.67-73, 2014. ,
Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition, Experimental and Therapeutic Medicine, vol.16, pp.2751-2755, 2018. ,
Verteporfin inhibits growth of human glioma in vitro without light activation, Scientific Reports, vol.7, issue.1, 2017. ,
Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells, Oncotarget, vol.8, issue.17, pp.28628-28640, 2017. ,
Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1, Science Signaling, vol.8, issue.397, pp.ra98-ra98, 2015. ,
Verteporfin inhibits YAP function through up-regulating 14-3-3? sequestering YAP in the cytoplasm, Am. J. Cancer Res, vol.6, pp.27-37, 2016. ,
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity, Journal of Experimental & Clinical Cancer Research, vol.38, issue.1, p.503, 2019. ,
A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma, Theranostics, vol.8, issue.12, pp.3256-3267, 2018. ,
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells, Oncotarget, vol.6, issue.36, pp.38854-38865, 2015. ,
Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127), Journal of Experimental & Clinical Cancer Research, vol.37, issue.1, 2018. ,
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4, Nature Medicine, vol.24, issue.10, pp.1599-1610, 2018. ,
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle, Nature Communications, vol.5, issue.1, p.3511, 2014. ,
Highlights in Resistance Mechanism Pathways for Combination Therapy, Cells, vol.8, issue.9, p.1013, 2019. ,
Mechanisms of acquired resistance to targeted cancer therapies, Future Oncology, vol.8, issue.8, pp.999-1014, 2012. ,
Cancer drug resistance: an evolving paradigm, Nature Reviews Cancer, vol.13, issue.10, pp.714-726, 2013. ,
Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance, Chinese Journal of Cancer, vol.35, issue.1, 2016. ,